+44 (0)1509 263171
Please use this identifier to cite or link to this item:
|Title: ||Overcoming the translational challenges of the effective administration and delivery of cells|
|Authors: ||Lyness, Alexander M.|
Williams, David J.
|Issue Date: ||2015|
|Publisher: ||© Elsevier Inc.|
|Citation: ||LYNESS, A.M., MEDCALF, N. and WILLIAMS, D.J, 2015. Overcoming the translational challenges of the effective administration and delivery of cells. Cytotherapy, 17 (6), pp.S83-S84.|
|Abstract: ||Of the few cell-based therapies widely available today the most mature are the treatment of blood-borne cancers and wound healing. The routes of administration for these applications are well understood and a great deal of research has resolved the many biological, pharmacological and engineering challenges associated with the delivery of cells by these methods.
These delivery methods are only suitable for a small proportion of the possible cell therapies. Many other treatments under development for illnesses that affect organs – such as diabetes, dermatological conditions and degenerative diseases – require more complex tools and methods to ensure cells are efficiently and effectively delivered to structures such as the pancreas, skin and brain. Injuries to musculoskeletal tissues such as cartilage, intra-vertebral disc and bone may be more easily accessed; however, they present different challenges, as the delivery methods must not reduce the long-term mechanical function of the tissue the treatment is attempting to repair.
Oversights can occur due to the reliance on existing and often unsuitable pre-clinical models for delivery and experimental methods and data that cannot be readily translated into the clinic. Different cell types and their behaviours will also lead to complications, so too will engineering challenges such as dosing accuracy, delivery to the appropriate site, engraftment and cell viability after shear and thermal stresses.
The delivery method and device used should be considered a crucial part of the cell therapy as a whole. Many companies in regenerative medicine have designed their own delivery device often in series, not in parallel, with the development of their product. As more treatments get closer to clinic many more different devices will be required, thus presenting opportunities for those who understand the generic delivery challenges in the field.|
|Description: ||This is a poster abstract from the 21st ISCT Annual Meeting.|
|Version: ||Accepted for publication|
|Publisher Link: ||http://dx.doi.org/10.1016/j.jcyt.2015.03.599|
|Appears in Collections:||Conference Papers and Contributions (Mechanical, Electrical and Manufacturing Engineering)|
Files associated with this item:
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.